The role of medicine donations in the global programme for the elimination of lymphatic filariasis.
The role of medicine donations in the global programme for the elimination of lymphatic filariasis.
复制标题
DOI：
10.1093/inthealth/ihaa077
复制
发表时间：
2020-12-22
影响因子：
2.5
通讯作者：
Gusovsky F
中科院分区：
文献类型：
--
作者：
Williams T;Taylor R;Iwamoto M;Hida T;Gusovsky F
1997年通过的世界卫生大会第50.29号决议要求世界卫生组织（世卫组织）及其成员国承诺消除作为公共卫生问题的淋巴丝虫病。2000年，为支持这一雄心勃勃的目标和70多个淋巴丝虫病流行国家的卫生部，创建了消除淋巴丝虫病全球方案。由此产生的世卫组织消除战略包括两个主要组成部分：通过阻断传播来阻止感染的传播，以及减轻受影响人口的痛苦（通过控制发病率）。该基金汇集了广泛的全球公共和私营行为者伙伴关系，包括总部设在三个不同大陆的三家制药公司。葛兰素史克公司、默沙东公司（默克公司的商品名，凯尼尔沃思，新泽西州，美国）和Escherai在GPELF的前20年取得了重大成就，并定位为GPELF的未来十年的目标提供重要贡献。当我们庆祝在GPELF的第一个20年期间消除LF的进展时，本文反映了导致创建三个捐赠计划的因素，这些计划所做的贡献以及沿着学到的一些教训。最后，我们强调我们继续致力于消除LF并展望下一个十年。
World Health Assembly Resolution 50.29, adopted in 1997, committed the World Health Organization (WHO) and its member states to eliminate lymphatic filariasis (LF) as a public health problem. In 2000, to support this ambitious goal and the health ministries in the >70 LF-endemic countries, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was created. The resulting WHO elimination strategy consists of two main components: to stop the spread of infection by interrupting transmission and to alleviate the suffering of affected populations (by controlling morbidity). The GPELF has brought together a broad global partnership of public and private actors, including three pharmaceutical companies with headquarters in three different continents. The medicine donations programmes from GlaxoSmithKline, MSD (trade name of Merck & Co. Inc., Kenilworth, NJ, USA) and Eisai have enabled significant achievements during the first 20 y of the GPELF and are positioned to provide essential contributions to the GPELF's goals for the next decade. As we celebrate the progress towards LF elimination during the GPELF's first 20 y, this article reflects on the factors that led to the creation of the three donation programmes, the contributions these programmes have made and some lessons learned along the way. We close by emphasizing our continued commitments to LF elimination and perspectives on the next decade.
登录
查看更多内容
DOI：
10.1056/nejmoa1706854
发表时间：
2018-11-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
King CL;Suamani J;Sanuku N;Cheng YC;Satofan S;Mancuso B;Goss CW;Robinson LJ;Siba PM;Weil GJ;Kazura JW
通讯作者：
Kazura JW
DOI：
10.1016/s0035-9203(98)90972-5
发表时间：
1998-01-01
影响因子：
2.2
作者：
Ismail, MM;Jayakody, RL;Dissanaike, AS
通讯作者：
Dissanaike, AS
影响因子：
4.5
作者：
Otsuji, Yoshihito
通讯作者：
Otsuji, Yoshihito
影响因子：
11.8
作者：
Turner, Hugo C.;Bettis, Alison A.;Bradley, Mark H.
通讯作者：
Bradley, Mark H.
影响因子：
3.8
作者：
Ichimori, Kazuyo;King, Jonathan D.;Ottesen, Eric A.
通讯作者：
Ottesen, Eric A.